Showing results (311-320 of 454) with videos related to
Sort By:
Pageof 46
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 21, 2017
Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral TherapyIra M Jacobson, Mary K Washington, Maria Buti, et al.Gastroenterology|October 11, 2016
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C InfectionPaul Kwo, Edward J Gane, Cheng-Yuan Peng, et al.Alimentary Pharmacology & Therapeutics|July 21, 2021
2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantationChristophe Duvoux, Luca S Belli, James Fung, et al.International Journal of Molecular Sciences|December 23, 2023
In-Host HEV Quasispecies Evolution Shows the Limits of Mutagenic Antiviral TreatmentsSergi Colomer-Castell, Josep Gregori, Damir Garcia-Cehic, et al.Alimentary Pharmacology & Therapeutics|August 12, 2025
Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of TreatmentGrace Lai-Hung Wong, Edward Gane, Calvin Q Pan, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 14, 2006
Chronic hepatitis B: a critical appraisal of current approaches to therapyRobert P Perrillo, Robert G Gish, Marion Peters, et al.Journal of Viral Hepatitis|May 21, 2019
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6Eric Lawitz, Edward Gane, Jordan J Feld, et al.Hepatology (Baltimore, Md.)|August 3, 2013
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR studyMichael W Fried, Maria Buti, Gregory J Dore, et al.Gut|January 25, 2023
Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infectionHarry L A Janssen, Jinlin Hou, Tarik Asselah, et al.The Lancet. Gastroenterology & Hepatology|April 13, 2019
Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B studyMilan J Sonneveld, Willem P Brouwer, Henry L-Y Chan, et al.Pageof 46